Taxotere® (docetaxel)

Taxotere® is indicated solely or in combination with another anticancer drug, according to the case, for the treatment of breast cancer in both the early stages (adjuvant treatment) and in the metastatic phase, as well as in the HER2/neu positive forms for which prognosis is very poor. Taxotere® is also indicated for the treatment of stage IV non-small cell lung cancer and for metastatic hormone-refractory prostate cancer.

Taxotere® (docetaxel) is a drug in the taxoid class, which inhibits cancer cell division by essentially “freezing” the cell’s internal skeleton, comprised of microtubules which assemble and disassemble during a cell cycle. Taxotere® promotes assembly and blocks disassembly, thereby preventing cancer cells from dividing and resulting in their death.

Taxotere® was first approved in 1995 and is currently marketed in over 100 countries in eight indications for four major forms of cancer positive forms.

In March 2006, Taxotere® received approval in the U.S. and Europe for the treatment of patients with metastatic gastric cancer.
The clinical development of Taxotere® continues, including diseases for which Taxotere® is already licensed, to give patients the benefit of Taxotere®’s efficacy at every stage of disease.